Pro Medicus (ASX:PME) Shares Command Perfection As Non Cash Profit Concerns Linger

Pro Medicus walked into these results with its stock already on a tear, up sharply over the past three months and closing at A$198.85 on 19 August. The market has been paying a rich multiple for perfection. The headline from this earnings release is simple: profitability remains extremely high, with net profit margin at 54.1%, yet the valuation now sits on a trailing P/E of 78.3x that leans heavily on non cash earnings.

That is the sentiment clash investors need to solve: enthusiasm for the story versus the price being asked for it.

Is Pro Medicus priced for another strong earnings run, or have the rich P/E and heavy non cash component already stretched expectations too far? Compare the market story with our valuation analysis for Pro Medicus

FY 2026 Earnings Summary

• Revenue (FY 2026 vs. FY 2025): A$261.69m vs. A$212.98m, a reported increase of 22.9%
• Net Income (Excl. Extra Items, FY 2026 vs. FY 2025): A$265.34m vs. A$115.22m, a reported increase of 130.3%
• Basic EPS (FY 2026 vs. FY 2025): A$2.54 per share vs. A$1.10 per share, a reported increase of 130.3%
• Net Profit Margin (FY 2026 vs. FY 2025): 54.1% vs. a lower margin in the prior year, indicating a reported margin improvement

Prefer clean charts instead of dense earnings tables and spreadsheets? See Pro Medicus' complete visual financial overview, including a clear view of its valuation in our company report for Pro Medicus.

Pro Medicus Bull Case Meets Concrete Contract Milestones

The bullish story around Pro Medicus is that a cloud native, transaction based imaging platform can turn large U.S. health systems into long term, high margin annuities. The FY26 result goes a long way to validating that idea. Revenue of US$261.7m and EBIT margins just under 75% sit alongside forward recurring revenue of about US$1.3b over five years. That is backed by 10 new contracts worth around US$407m in minimums and a 100% renewal record, with deals such as Allegheny and Wexner renewed on higher pricing and minimums.

The thesis also leans on expansion beyond radiology and deeper workflow integration. In this area, Pro Medicus is also hitting milestones. Cardiology is now included in deals such as TidalHealth, digital pathology and Visage reporting are live in Europe, and AI optimised reporting and integrations are already being deployed ahead of planned U.S. launches.

Reveal where the surface looks calm as the multi year models start to disagree on Pro Medicus. Access the full revenue, margin and EPS trajectory in the analyst estimates for Pro Medicus.

Pro Medicus Bear Case: Execution Risks Still Unproven

Bears argue Pro Medicus is one delay away from a revenue air pocket, that cloud costs will erode margins and that adjacencies like cardiology and digital pathology will stay niche. This result does not neatly confirm those fears, but it also does not clear them.

On execution, management describes FY26 as the busiest implementation year and flags Trinity at approximately 87% complete. There is no disclosure of material client driven delays or scope cuts that would validate concerns about stalled rollouts or slower revenue recognition. Forward recurring revenue of about US$1.3b over five years and 6 out of 6 renewals at higher pricing also work against the idea of immediate contract fragility.

The bear story leans more on what is not yet visible. Cardiology and digital pathology are present in contracts but still early. U.S. go live for some products is guided for early 2027, so diversification away from U.S. radiology volumes remains largely untested in the reported numbers.

With Pro Medicus still early in cardiology and digital pathology, and with such a high level of non cash earnings, it is worth asking whether execution risks and accounting quality concerns are fully visible. Review the independent risk scoring and hidden warning signs flagged in our risk analysis for Pro Medicus which shows 1 important warning sign.

Stay Ahead With Simply Wall St

If the rich P/E multiple and heavy non cash component around Pro Medicus have your attention, register for free with Simply Wall St and add it to a Watchlist to track share price moves against fair value and spot a more informed entry point. Once you own shares, use the Portfolio Command Center to focus on the key financial and fundamental updates that matter most to your holdings. For a longer term view, join the Community to see how other investors are thinking about the same risks and opportunities. This way you can surface potential catalysts and red flags earlier and give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Pro Medicus?

Fresh stock ideas can move from under the radar to flying higher before most investors react. Use these curated lists while the information still matters and get in early.

• Spot cash generative compounders before momentum headlines catch up by scanning our curated 14 high quality undervalued stocks that blend strong cash flows with resilient balance sheets.
• Ride the structural shift toward smarter grids and transmission upgrades with a focused set of 39 power grid technology and infrastructure stocks that benefit from infrastructure investment trends.
• Position around real assets the moment sentiment swings by reviewing carefully filtered 30 elite gold producer stocks that target established producers rather than speculative explorers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com